Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEX168 + simvastatin
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
**PEX168 + simvastatin** is a combination of two pharmaceutical agents: pegloxenatide (PEX168), a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist primarily investigated for type 2 diabetes, and simvastatin, an oral HMG-CoA reductase inhibitor ("statin") widely used to reduce cholesterol levels and prevent cardiovascular disease. The combination has been studied for potential pharmacokinetic interactions and efficacy/safety in type 2 diabetes contexts, with simvastatin acting by inhibiting cholesterol biosynthesis and pegloxenatide by enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Mechanistically, the pairing targets both dyslipidemia and glucose control.
- Brand names
- ZocorCholibFloLipidSimcorVytorin
- Other names
- pegloxenatide + simvastatin
02
Targets
GLP1R (GLP-1R)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on PEX168 + simvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEX168 + simvastatin.